MedTrace Logo

Teletherapy vs. In-Person Cognitive Behavioral Therapy for Generalized Anxiety Disorder

NCT07119515 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-08-13

No results posted yet for this study

Summary

The goal of this randomized controlled trial is to compare the clinical efficacy of teletherapy versus in-person third-wave cognitive behavioral therapy (CBT) in treating generalized anxiety disorder (GAD) among young individuals aged 18-45 years in Pakistan. The main questions it aims to answer are:

* Is teletherapy as effective as in-person therapy in reducing anxiety symptoms and stress?
* Do therapeutic alliance, treatment adherence, and social support influence treatment outcomes differently across delivery methods? Researchers will compare the teletherapy group (remote sessions via digital platforms) and the in-person therapy group (face-to-face sessions) to evaluate differences in symptom reduction, general health improvement, and moderating factors like therapeutic alliance.

Participants will:

* Undergo a 8-week intervention with weekly structured third-wave CBT sessions.
* Complete assessments at baseline, post-intervention, and follow-up using validated scales (e.g., Generalized Anxiety Disorder-7 \[GAD-7\], Hamilton Anxiety Rating Scale \[HAM-A\]).
* Engage in modules including mindfulness, behavioral activation, and exposure therapy, adapted for their assigned delivery method.

This study aims to address gaps in mental health accessibility in Pakistan by evaluating whether teletherapy can serve as a viable alternative to traditional in-person care.

Conditions

  • Generalized Anxiety Disorder

Interventions

BEHAVIORAL

Third-Wave CBT via Teletherapy

Twelve weekly 40-minute remote sessions via video conferencing, including mindfulness, behavioral activation, and exposure therapy.

BEHAVIORAL

Third-Wave CBT In-Person

Twelve weekly 40-minute face-to-face sessions with identical third-wave CBT content.

Sponsors & Collaborators

  • Allied Hospital Faisalabad

    collaborator OTHER

  • Government College University Faisalabad

    lead OTHER

Principal Investigators

  • Imaan Sabeeh, MS Scholar · Government College University Faisalabad

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-10
Primary Completion
2025-08-26
Completion
2025-08-26

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07119515 on ClinicalTrials.gov